Cowealth Medical Holding Co's Days Sales Outstanding for the
three
months ended in Dec. 2025 was 512.8.
Cowealth Medical Holding Co's Days Inventory for the
three
months ended in Dec. 2025 was 132.55.
Cowealth Medical Holding Co's Days Payable for the
three
months ended in Dec. 2025 was 104.15.
Therefore, Cowealth Medical Holding Co's Cash Conversion Cycle (CCC) for the
three
months ended in Dec. 2025 was 541.20.
Cowealth Medical Holding Co (ROCO:4745) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Cowealth Medical Holding Co Cash Conversion Cycle Related Terms
Cowealth Medical Holding Co Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical Holding Co Cash Conversion Cycle Chart
ROCO:4745 vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, Cowealth Medical Holding Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cowealth Medical Holding Co Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cowealth Medical Holding Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Cowealth Medical Holding Co's Cash Conversion Cycle falls into.
Cowealth Medical Holding Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Cowealth Medical Holding Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cowealth Medical Holding Co (ROCO:4745) has a Cash Conversion Cycle of 541.20 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cowealth Medical Holding Co and its competitors.
Is Cowealth Medical Holding Co's Cash Conversion Cycle too high?
Cowealth Medical Holding Co's current Cash Conversion Cycle is 541.20. The Medical Devices & Instruments industry median Cash Conversion Cycle is 157.71. Cowealth Medical Holding Co's value of 541.20 is 243.2% above this industry median. Overall, Cowealth Medical Holding Co has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical Holding Co's Cash Conversion Cycle compare to ABT and SYK?
Cowealth Medical Holding Co's Cash Conversion Cycle of 541.20 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 157.71. Cowealth Medical Holding Co's value of 541.20 is 243.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 157.71, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cowealth Medical Holding Co's current Cash Conversion Cycle of 541.20 is 243.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Cowealth Medical Holding Co and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 157.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cowealth Medical Holding Co's current Cash Conversion Cycle is 541.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical Holding Co (ROCO:4745) is currently considered Fairly Valued. The stock's GF Value™ is NT$13.11, compared to a current price of NT$13.80 — trading 5.3% above its estimated fair value. The current Cash Conversion Cycle is 541.20 and 243.2% above the Medical Devices & Instruments industry median of 157.71. Cowealth Medical Holding Co's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Cowealth Medical Holding Co (ROCO:4745), the current Cash Conversion Cycle is 541.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cowealth Medical Holding Co (ROCO:4745) Overvalued in 2026?
Based on GuruFocus' analysis, Cowealth Medical Holding Co stock appears to be overvalued.
The current stock price of NT$13.80 is trading 5.3% above its estimated GF Value™ of NT$13.11.
GuruFocus considers Cowealth Medical Holding Co to be Fairly Valued.
Key valuation signals for ROCO:4745:
Cash Conversion Cycle: 541.20
GF Value™: NT$13.11 vs. price of NT$13.80 (5.3% above fair value)
Industry Position: 243.2% above the Medical Devices & Instruments median
No single metric tells the full story. See the ROCO:4745 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cowealth Medical Holding Co Ltd is mainly involved in trading medical equipment, reagents, and spare parts. Its wide range of solutions includes refined management services tailored for in-vitro diagnostic products, reagents, and consumables, an integrated platform designed for decision-making and analysis, commercialization of achievements in medical science and technology, a Multi-Channel Coaxial Time Audio Video Imaging Platform (MCCTAVIP), and an AI-assisted system for clinical diagnosis. The Group has two reportable segments: Segment A, which generates maximum revenue and sells equipment, and Segment B, which sells reagents and others. Geographically, it generates maximum revenue from China and Hong Kong, and the rest from Taiwan.
50GF Score
Get the complete analysis for ROCO:4745
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4745 has been successfully added to your 
